Guillain-Barré syndrome.

Area of Science:

• Neurology
• Immunology
• Peripheral Nervous System Disorders

Background:

• Guillain-Barré syndrome (GBS) is an acute autoimmune peripheral neuropathy.
• Often preceded by infections, GBS pathophysiology involves cross-reactivity between microbial and neural antigens, potentially leading to antiganglioside antibodies.
• The condition causes progressive weakness, potential respiratory failure, dysautonomia, and can result in significant long-term disability or death.

Purpose of the Study:

• To provide a comprehensive overview of Guillain-Barré syndrome.
• To discuss the pathophysiology, diagnosis, and multidisciplinary treatment of GBS.
• To evaluate the efficacy of different treatment modalities for GBS.

Main Methods:

• Review of existing literature on Guillain-Barré syndrome.
• Analysis of diagnostic criteria including electrophysiology and cerebrospinal fluid evaluation.
• Assessment of treatment outcomes for plasma exchange, intravenous immunoglobulin (IVIg), and corticosteroids.

Main Results:

• GBS is characterized by rapid onset weakness, with nadir typically reached within 2-4 weeks.
• Diagnostic support comes from electrophysiological studies and cerebrospinal fluid analysis.
• Plasma exchange and IVIg are effective treatments for reducing GBS severity and residual deficits.
• Corticosteroids have shown no efficacy in treating GBS.

Conclusions:

• GBS requires a multidisciplinary approach for optimal patient management.
• Early diagnosis and treatment with plasma exchange or IVIg are crucial for improving prognosis.
• Understanding the autoimmune basis and triggers of GBS is key to developing effective therapies.